Cargando…
Quantitative Proteomic Analysis Identifies Targets and Pathways of a 2-Aminobenzamide HDAC Inhibitor in Friedreich’s Ataxia Patient iPSC-Derived Neural Stem Cells
[Image: see text] Members of the 2-aminobenzamide class of histone deacetylase (HDAC) inhibitors show promise as therapeutics for the neurodegenerative diseases Friedreich’s ataxia (FRDA) and Huntington’s disease (HD). While it is clear that HDAC3 is one of the important targets of the 2-aminobenzam...
Autores principales: | Shan, Bing, Xu, Chunping, Zhang, Yaoyang, Xu, Tao, Gottesfeld, Joel M., Yates, John R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2014
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4227551/ https://www.ncbi.nlm.nih.gov/pubmed/24933366 http://dx.doi.org/10.1021/pr500514r |
Ejemplares similares
-
Mechanism of Action of 2-Aminobenzamide HDAC Inhibitors in Reversing Gene Silencing in Friedreich’s Ataxia
por: Soragni, Elisabetta, et al.
Publicado: (2015) -
Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model
por: Sandi, Chiranjeevi, et al.
Publicado: (2011) -
HDAC Inhibitors Correct Frataxin Deficiency in a Friedreich Ataxia Mouse Model
por: Rai, Myriam, et al.
Publicado: (2008) -
Improved Histone Deacetylase Inhibitors as Therapeutics for the Neurodegenerative Disease Friedreich's Ataxia: A New Synthetic Route
por: Xu, Chunping, et al.
Publicado: (2011) -
New Insights into the Hepcidin-Ferroportin Axis and Iron Homeostasis in iPSC-Derived Cardiomyocytes from Friedreich's Ataxia Patient
por: Bolotta, Alessandra, et al.
Publicado: (2019)